StockWatch
·
Filing
Q2

Fermenta Biotech Ltd

FERMENTAFY2611 Nov 2025
Revenue-4.4%
Net Profit-16.5%
OPM20.45%

P&L

Quarterly Consolidated

Revenue
-4.4%130.22
Expenditure
-4.6%111.57
Net Profit
-16.5%18.03
NPM 13.29%-10.8%EPS ₹6.48-13.5%

vs Q1 FY26

Fermenta Biotech's H1FY26 Consolidated Revenues Surge 57%, Net Profit Soars 664% YoY

11 Nov 2025 · 11 Nov 2025, 05:37 pm

Summary

Fermenta Biotech Limited, a leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals, announced its financial results for H1FY26. The company's consolidated revenue (other than from real estate) was INR 275.2 crore, up 59% from the same year-ago period. EBITDA for the same period was INR 67.2 crore, up 155%. The human nutrition segment volumes grew 74% over H1FY25, and the animal nutrition segment volumes grew 6% with a 35% increase in average realization.

Key Highlights

  1. 1

    Consolidated Revenues for H1FY26: INR 280.7 crore, up by INR 101.8 crore YoY

  2. 2

    Consolidated EBITDA for H1FY26: INR 69.1 crore, up 173% YoY

  3. 3

    Q2FY26 Consolidated Revenues: INR 135.7 crore, up 39% YoY; down 6% QoQ

  4. 4

    Human nutrition segment volumes grew 74% over H1FY25

  5. 5

    Animal nutrition segment volumes grew 6% and average realization rose 35% over H1IFY25

  6. 6

    Other Income includes non-recurring insurance claim received amounting to INR 2.7 crore in QIFY26 and H1FY26

  7. 7

    German toll manufacturing subsidiary's HIFY26 revenue: INR 34.3 crores, up 194% YoY

  8. 8

    US trading business subsidiary's HIFY26 revenue: INR 30.3 crore, up 68% from a year ago

Management Comments

P

Prashant Nagre

Managing Director

The turnaround of FY25 was further confirmed in H1FY26. While core revenue growth, excluding that from real estate unlocking, in FY25 over FY24 was 57%, H1FY26 excluding that from real estate unlocking, the revenue was already 64.5% of that achieved in full FY25. EBITDA in H1FY26, excluding real estate, was 81% of the total EBITDA for FY25. The process patent for the production of completely vegan and vegetarian-friendly Vitamin D3 will help Fermenta capture emerging global opportunities across nutraceuticals and food fortification sectors, where sustainable, plant-derived ingredients command premiums and growing market share. The transfer of our environmental solutions portfolio to a dedicated subsidiary creates a focused entity that can target accelerated growth in this critical sector.

Informational and educational content only. Not investment advice.